tirzepatide and liver enzymes Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic disease by reducing the expression of CD36 OBP2A Dual GIP and GLP-1 receptor

Dermatol Clin 16 : 313320 Silverman MK et al

For those with complications from diabetes, such as kidney or liver problems, adding oral contraceptives to a treatment plan with semaglutide may create further health risks

It is sold under different brands names such as Ozempic, Weygovy and Rybelsus

Microbial trimethylamine (TMA), converted in the liver to trimethylamine-N-oxide (TMAO), further links gut ecology to cardiometabolic injury by affecting cholesterol trafficking, endothelial reactivity, and platelet responses

Because semaglutide can cause marked weight loss and changes in blood pressure or hydration in some people, clinicians have hypothesized that these physiologic changes might contribute to risk in vulnerable individuals although the mechanism is not fully understood